Crossref
Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?
AME Clinical Trials Review · 2026-04 · 4 · 18-18
DOI: 10.21037/actr-25-101 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-04. Verfasst von Alice Cattelani und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Cattelani, A., & Frigerio, I. (2026). Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?. AME Clinical Trials Review, 4, 18-18. https://doi.org/10.21037/actr-25-101
Vancouver
Cattelani A, Frigerio I. Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?. AME Clinical Trials Review. 2026;4:18-18. doi:10.21037/actr-25-101
BibTeX
@article{Cattelani2026,
author = {Cattelani, Alice and Frigerio, Isabella},
title = {Reframing the immunotherapy landscape in borderline resectable pancreatic ductal adenocarcinoma: progress or plateau?},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {18--18},
doi = {10.21037/actr-25-101}
}
EUVIMED